Shimoli Barot, MD, discusses PATINA data showing improved PFS with palbociclib-based maintenance in HR-positive, HER2-positive metastatic breast cancer.
Shimoli Barot, MD
Advertisement
Shimoli Barot, MD, is of Cleveland Clinic
Articles by Shimoli Barot, MD
Shimoli Barot, MD, highlights the role of maintenance palbociclib plus trastuzumab, pertuzumab, and endocrine therapy in HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
4
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
5